New combo tackles resistant prostate cancer
Disease control
Completed
This early-phase trial tested a new drug (ARV-110) combined with the standard drug abiraterone in 45 men whose metastatic prostate cancer was worsening despite abiraterone alone. The main goals were to check safety and find the best dose. The study is complete, but results are no…
Phase: PHASE1 • Sponsor: Arvinas Androgen Receptor, Inc. • Aim: Disease control
Last updated Apr 30, 2026 15:51 UTC